Literature DB >> 34981720

Kinetic Characteristics of Neutralizing Antibody Responses Vary among Patients with COVID-19.

Ling Hua Li1, Hong Wei Tu2, Dan Liang2, Chun Yan Wen1, An An Li3, Wei Yin Lin1, Ke Qi Hu3, Wen Shan Hong4, Yue Ping Li1, Juan Su2, San Tao Zhao1, Wei Li2, Run Yu Yuan2, Ping Ping Zhou2, Feng Yu Hu1, Xiao Ping Tang1, Chang Wen Ke2, Bi Xia Ke2, Wei Ping Cai1.   

Abstract

OBJECTIVE: The coronavirus disease 2019 (COVID-19) pandemic continues to present a major challenge to public health. Vaccine development requires an understanding of the kinetics of neutralizing antibody (NAb) responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
METHODS: In total, 605 serum samples from 125 COVID-19 patients (from January 1 to March 14, 2020) varying in age, sex, severity of symptoms, and presence of underlying diseases were collected, and antibody titers were measured using a micro-neutralization assay with wild-type SARS-CoV-2.
RESULTS: NAbs were detectable approximately 10 days post-onset (dpo) of symptoms and peaked at approximately 20 dpo. The NAb levels were slightly higher in young males and severe cases, while no significant difference was observed for the other classifications. In follow-up cases, the NAb titer had increased or stabilized in 18 cases, whereas it had decreased in 26 cases, and in one case NAbs were undetectable at the end of our observation. Although a decreasing trend in NAb titer was observed in many cases, the NAb level was generally still protective.
CONCLUSION: We demonstrated that NAb levels vary among all categories of COVID-19 patients. Long-term studies are needed to determine the longevity and protective efficiency of NAbs induced by SARS-CoV-2.
Copyright © 2021 The Editorial Board of Biomedical and Environmental Sciences. Published by China CDC. All rights reserved.

Entities:  

Keywords:  Kinetics; Neutralizing antibody; SARS-CoV-2; Sex

Mesh:

Substances:

Year:  2021        PMID: 34981720      PMCID: PMC8747431          DOI: 10.3967/bes2021.133

Source DB:  PubMed          Journal:  Biomed Environ Sci        ISSN: 0895-3988            Impact factor:   3.118


  19 in total

1.  Kinetics of viral load and antibody response in relation to COVID-19 severity.

Authors:  Yanqun Wang; Lu Zhang; Ling Sang; Feng Ye; Shicong Ruan; Bei Zhong; Tie Song; Abeer N Alshukairi; Rongchang Chen; Zhaoyong Zhang; Mian Gan; Airu Zhu; Yongbo Huang; Ling Luo; Chris Ka Pun Mok; Manal M Al Gethamy; Haitao Tan; Zhengtu Li; Xiaofang Huang; Fang Li; Jing Sun; Yanjun Zhang; Liyan Wen; Yuming Li; Zhao Chen; Zhen Zhuang; Jianfen Zhuo; Chunke Chen; Lijun Kuang; Junxiang Wang; Huibin Lv; Yongliang Jiang; Min Li; Yimin Lin; Ying Deng; Lan Tang; Jieling Liang; Jicheng Huang; Stanley Perlman; Nanshan Zhong; Jingxian Zhao; J S Malik Peiris; Yimin Li; Jincun Zhao
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

2.  Microneutralization test for the determination of mumps antibody in vero cells.

Authors:  M T Kenny; K L Albright; R P Sanderson
Journal:  Appl Microbiol       Date:  1970-09

Review 3.  Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease.

Authors:  Jasper F W Chan; Susanna K P Lau; Kelvin K W To; Vincent C C Cheng; Patrick C Y Woo; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

4.  Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients.

Authors:  Fengting Yu; Liting Yan; Nan Wang; Siyuan Yang; Linghang Wang; Yunxia Tang; Guiju Gao; Sa Wang; Chengjie Ma; Ruming Xie; Fang Wang; Chianru Tan; Lingxiang Zhu; Yong Guo; Fujie Zhang
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

Review 5.  Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.

Authors:  Eskild Petersen; Marion Koopmans; Unyeong Go; Davidson H Hamer; Nicola Petrosillo; Francesco Castelli; Merete Storgaard; Sulien Al Khalili; Lone Simonsen
Journal:  Lancet Infect Dis       Date:  2020-07-03       Impact factor: 25.071

6.  Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans.

Authors:  Anu Haveri; Nina Ekström; Anna Solastie; Camilla Virta; Pamela Österlund; Elina Isosaari; Hanna Nohynek; Arto A Palmu; Merit Melin
Journal:  Eur J Immunol       Date:  2021-10-08       Impact factor: 6.688

7.  Convergent antibody responses to SARS-CoV-2 in convalescent individuals.

Authors:  Davide F Robbiani; Christian Gaebler; Frauke Muecksch; Julio C C Lorenzi; Zijun Wang; Alice Cho; Marianna Agudelo; Christopher O Barnes; Anna Gazumyan; Shlomo Finkin; Thomas Hägglöf; Thiago Y Oliveira; Charlotte Viant; Arlene Hurley; Hans-Heinrich Hoffmann; Katrina G Millard; Rhonda G Kost; Melissa Cipolla; Kristie Gordon; Filippo Bianchini; Spencer T Chen; Victor Ramos; Roshni Patel; Juan Dizon; Irina Shimeliovich; Pilar Mendoza; Harald Hartweger; Lilian Nogueira; Maggi Pack; Jill Horowitz; Fabian Schmidt; Yiska Weisblum; Eleftherios Michailidis; Alison W Ashbrook; Eric Waltari; John E Pak; Kathryn E Huey-Tubman; Nicholas Koranda; Pauline R Hoffman; Anthony P West; Charles M Rice; Theodora Hatziioannou; Pamela J Bjorkman; Paul D Bieniasz; Marina Caskey; Michel C Nussenzweig
Journal:  Nature       Date:  2020-06-18       Impact factor: 69.504

8.  In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age.

Authors:  Nicole A P Lieberman; Vikas Peddu; Hong Xie; Lasata Shrestha; Meei-Li Huang; Megan C Mears; Maria N Cajimat; Dennis A Bente; Pei-Yong Shi; Francesca Bovier; Pavitra Roychoudhury; Keith R Jerome; Anne Moscona; Matteo Porotto; Alexander L Greninger
Journal:  PLoS Biol       Date:  2020-09-08       Impact factor: 8.029

View more
  1 in total

1.  Genomic Epidemiology of Imported Cases of COVID-19 in Guangdong Province, China, October 2020 - May 2021.

Authors:  Dan Liang; Tao Wang; Jiao Jiao Li; Da Wei Guan; Guan Ting Zhang; Yu Feng Liang; An An Li; Wen Shan Hong; Li Wang; Meng Lin Chen; Xiao Ling Deng; Feng Juan Chen; Xing Fei Pan; Hong Ling Jia; Chun Liang Lei; Chang Wen Ke
Journal:  Biomed Environ Sci       Date:  2022-05-20       Impact factor: 2.831

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.